Genomic Advances in Heart Failure

Benoit Tyl, MD, FESC, Medical and Scientific Director, Cardiology, Servier

Dr. Benoit Tyl is the scientific and medical director of cardiology at Servier (France). He is a cardiologist with a strong experience as a clinician and a fellow of the European Society of Cardiology. He worked for the pharmaceutical industry R&D since more than 15 years in various companies as well as in various positions. Within Servier, he worked in the past years on several cardiovascular R&D projects related to ischemic cardiomyopathies, arrhythmia and Heart Failure. He served 5 years as director of translational cardiovascular R&D within the company. In this position he supported Servier’s Cardiovascular projects from basic science to the marketing authorization, mainly on Heart Failure. One of his main focus is to help fill the gap between the idea (target) and the drug, especially with regards to target validation, population selection, preclinical and clinical studies using various methods and techniques including biomarkers. He is working closely with researchers, developers, but also various specialists within Servier and outside. The improvement in clinical trials, particularily within cardiology is one of his other topics of interest. He is also leading for Servier several international public-private international efforts contributing to drug development including the IMI BigData@Heart.

Irene Blat, PhD, Senior Director of Data Products and Analytics, Genuity Science

Irene Blat leads the product and analytics strategy for Genuity Science cohorts, platform and sequencing businesses. She brings 15 years of experience in genomics across academia, industry and IP law. Irene began her career at the Broad Institute where she helped launch the Connectivity Map, a database triangulating the link between gene perturbation, disease and function.

During her graduate studies at the Koch Institute of Integrative Cancer Research at MIT, Irene investigated the role of genetic modifiers in the progression of lung and colorectal tumors. Her work led to the identification of the timing and spatial distribution of important genes in early and mature intestinal stem cell differentiation. She has since held a research role at Massachusetts General Hospital and later served as a Technology Specialist at the IP law firm Clark & Elbing. Irene holds a BS in Biology from Duke University and a PhD in Genetics from MIT.

(Host) Ellen Gordon, PhD, Vice President, Business Development, Genuity Science

Ellen Gordon joined the commercial team at Genuity Science in 2020 with responsibility for cohort program sales and business development across several key pharmaceutical accounts.  Ellen has over 20 years of experience in healthcare and pharmaceutical research. Prior to joining Genuity Science, Ellen was responsible for sales and client solutions at GNS Healthcare, a leading provider of analytic solutions to pharmaceutical and health plan customers. Prior to that, she held senior positions at national and international market research firms where she gained an extensive background in designing and executing strategic custom research solutions globally.

Ellen holds a B.A. in Politics from Brandeis University, an M.A. in Russian Studies from Georgetown University and a Ph.D. in Political Science from the University of Michigan.